Article
Medicine, Research & Experimental
Rupesh Jain, Milan Paul, Sri Ganga Padaga, Sunil Kumar Dubey, Swati Biswas, Gautam Singhvi
Summary: The study introduces lipidic nanoparticles loaded with curcumin and chlorin e6 that generate reactive oxygen species (ROS) upon activation by near-infrared light, which show promise for treating aggressive cutaneous melanomas. The optimized nanoparticle formulation exhibited a small particle size and high entrapment efficiency. Co-delivery of curcumin and chlorin e6 enhanced cellular uptake, inhibited cancer growth, and induced apoptosis compared to free drug. The nanoparticles also achieved better skin permeation and retention, demonstrating their potential synergy.
MOLECULAR PHARMACEUTICS
(2023)
Article
Infectious Diseases
Alba Calvo, Esther Moreno, Irati Aldalur, Carmen Sanmartin, Esther Larrea, Elena Gonzalez-Penas, Juan Manuel Irache, Socorro Espuelas
Summary: This study evaluated the efficacy and safety of a topical berberine cream in BALB/c mice infected with Leishmania major parasites. The results showed that the cream was able to reduce lesion size, decrease parasite load, and promote wound healing. However, the relationship between drug plasma levels and in vivo effect was unclear.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2022)
Article
Instruments & Instrumentation
Ma. Florencia Peralta, Nadina A. Usseglio, Ma. Estefania Bracamonte, Ma. Laura Guzman, Ma. Eugenia Olivera, J. Diego Marco, Paola A. Barroso, Dolores C. Carrer
Summary: Topical treatment with dispersions containing miltefosine and different liposome compositions has shown to be effective in treating cutaneous leishmaniasis. Fluid liposomes can accelerate lesion healing and reduce the time needed to eliminate viable parasites from the lesion site.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH
(2022)
Article
Pharmacology & Pharmacy
Juliane S. Lanza, Virginia M. R. Vallejos, Guilherme S. Ramos, Ana Carolina B. de Oliveira, Cynthia Demicheli, Luis Rivas, Sebastien Pomel, Philippe M. Loiseau, Frederic Frezard
Summary: This study evaluates the effectiveness of nanoassemblies made from antimony(V) complexes with octanoyl-N-methylglucamide (SbL8) or decanoyl-N-methylglucamide (SbL10) in targeting infection sites in visceral and cutaneous leishmaniases. The results show that these nanoassemblies are stable at neutral pH and effectively accumulate in macrophages and the liver. SbL10 exhibits higher activity against intramacrophage Leishmania amastigotes and can be further enhanced with co-incorporated miltefosine. In vivo, NanoSb demonstrates high antileishmanial activity in murine models of VL and CL. This study supports the potential of NanoSb as a better delivery system for antimony and co-incorporated drugs compared to conventional antimonial Glucantime (R).
Article
Instruments & Instrumentation
Manuela Carvalheiro, Jennifer Vieira, Catarina Faria-Silva, Joana Marto, Sandra Simoes
Summary: Cutaneous leishmaniasis (CL) is a chronic skin disease characterized by skin lesions that may cause permanent scars. This study optimized a deformable lipid vesicle (DLV) for the topical administration of Amphotericin B (AmB) and found it to be effective in reducing parasite viability in skin layers. DLV may represent a cost-effective and safe therapeutic option in CL treatment.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH
(2021)
Article
Pharmacology & Pharmacy
Sarah Kymberly Santos de Lima, italo Novaes Cavallone, Dolores Remedios Serrano, Brayan J. Anaya, Aikaterini Lalatsa, Marcia Dalastra Laurenti, Joao Henrique Ghilardi Lago, Dalete Christine da Silva Souza, Gabriela Pustiglione Marinsek, Beatriz Soares Lopes, Renata de Britto Mari, Luiz Felipe Domingues Passero, Bozena B. Michniak-Kohn
Summary: This study developed a topical formulation containing 8-HQ and demonstrated its efficacy in experimental cutaneous leishmaniasis. The formulation was able to reduce parasite burden and lesion size without causing significant side effects.
Review
Pharmacology & Pharmacy
Sangseo Kim, Candace M. Day, Yunmei Song, Amy Holmes, Sanjay Garg
Summary: Non-melanoma skin cancer (NMSC) is a common malignancy globally, and topical treatment is a key management strategy. However, conventional topical treatments often face challenges such as poor drug penetration and patient adherence. To overcome these limitations, researchers have started using advanced topical patches for the treatment of NMSC. This review provides an overview of NMSC and the current landscape of topical treatments, focusing on the emerging technology of topical patches, and discusses their potential to improve existing therapies.
Article
Pharmacology & Pharmacy
Lin Chen, Liangju Kuang, Amy E. E. Ross, Wissam Farhat, Nikolay Boychev, Sina Sharfi, Levi N. N. Kanu, Longqian Liu, Daniel S. S. Kohane, Joseph B. B. Ciolino
Summary: This study developed a contact lens device that can release miltefosine for the treatment of Acanthamoeba keratitis. The contact lens showed sustained drug release and good biocompatibility, indicating its potential as a successful treatment method.
Article
Immunology
JeanAnne M. Ware, Elise M. O'Connell, Thomas Brown, Lauren Wetzler, Kawsar R. Talaat, Thomas B. Nutman, Theodore E. Nash
Summary: This study evaluated the use of miltefosine in 26 CL patients, showing a 77% cure rate with various Leishmania species. Common adverse events included nausea/vomiting (97%) and lack of appetite (54%), with some patients requiring treatment adjustments. Despite imperfect efficacy, miltefosine is considered a viable alternative treatment for CL due to its oral administration, broad efficacy, and manageable toxicities.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Immunology
Paulo R. L. Machado, Fernanda V. O. Prates, Viviane Boaventura, Taina Lago, Luiz H. Guimaraes, Albert Schriefer, Temis W. F. Corte, Gerson Penna, Aldina Barral, Manoel Barral-Netto, Edgar M. Carvalho
Summary: The study showed that miltefosine is more effective than pentavalent antimony for treating cutaneous leishmaniasis caused by L. braziliensis in Brazil, and it accelerates healing time. However, combining miltefosine with GM-CSF did not improve therapeutic outcome but did shorten the healing time.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Public, Environmental & Occupational Health
Sheridan Joseph, Timothy J. Whitman, Frederick S. Buckner, Anna L. Cogen
Summary: This case highlights the potential for treatment failure in cutaneous leishmaniasis caused by L. braziliensis, emphasizing the importance of clinical monitoring.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
(2021)
Article
Medicine, Research & Experimental
Guilherme S. Ramos, Virginia M. R. Vallejos, Marina S. Ladeira, Priscila G. Reis, Daniel M. Souza, Yuri A. Machado, Luiz O. Ladeira, Mauricio B. Pinheiro, Maria N. Melo, Ricardo T. Fujiwara, Frederic Frezard
Summary: The study found that fullerol has potential anti-leishmanial activity, especially when combined with liposomes, showing significant reduction in parasite load. This innovative approach provides a new potential method for treating VL.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Pharmacology & Pharmacy
Lidia Ballell-Hosa, Elisabet Gonzalez-Mira, Hector Santana, Judit Morla-Folch, Marc Moreno-Masip, Yaima Martinez-Prieto, Albert Revuelta, Primiano Pio Di Mauro, Jaume Veciana, Santi Sala, Lidia Ferrer-Tasies, Nora Ventosa
Summary: Topical delivery is of great interest due to localized drug delivery, patient compliance, and low risk for side effects. The DELOS nanovesicles drug delivery platform has shown potential for complex wound treatment and has been successfully formulated into hydrogels with improved stability and rheological properties. This has not been widely reported in literature, and further experiments have demonstrated enhanced bioactivity of integrated proteins in the gellified nanovesicles compared to liquid form.
Article
Pharmacology & Pharmacy
Hoda Awad, Mutasem Rawas-Qalaji, Rania El Hosary, Jayalakshmi Jagal, Iman Saad Ahmed
Summary: This study aims to improve the efficacy of topically applied ivermectin (IVM) by modifying its physical and chemical characteristics through nanocrystallization. The optimized IVM-nanocrystals demonstrated improved water-solubility, dissolution rate, and skin penetration, which could enhance the treatment of local parasitic infections.
INTERNATIONAL JOURNAL OF PHARMACEUTICS-X
(2023)
Article
Nanoscience & Nanotechnology
Duy-Thuc Nguyen, Min-Hwan Kim, Na-Young Yu, Min-Jun Baek, Kyung-Sun Kang, Ki Won Lee, Dae-Duk Kim
Summary: A novel bentonite-based composite formulation of orobol was prepared and found to significantly enhance the deposition of orobol in the skin. The addition of phosphatidylcholine improved the dissolution and release of orobol. Physicochemical characterizations and toxicity studies confirmed the safety and biocompatibility of the formulation.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2022)
Article
Medicine, Research & Experimental
Minshan Guo, Ke Wang, Ning Qiao, Vanessa Yardley, Mingzhong Li
MOLECULAR PHARMACEUTICS
(2018)
Article
Chemistry, Medicinal
Catherine Fagundez, Diver Sellanes, Stella Pena, Laura Scarone, Anna C. C. Aguiar, Juliana O. de Souza, Rafael V. C. Guido, Lindsay Stewart, Vanessa Yardley, Sabine Ottilie, Elizabeth A. Winzeler, Francisco-J. Gamo, Laura M. Sanz, Gloria L. Serra
ACS MEDICINAL CHEMISTRY LETTERS
(2019)
Article
Parasitology
Katrien Van Bocxlaer, Diana Caridha, Chad Black, Brian Vesely, Susan Leed, Richard J. Sciotti, Gert-Jan Wijnant, Vanessa Yardley, Stephanie Braillard, Charles E. Mowbray, Jean-Robert Ioset, Simon L. Croft
INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE
(2019)
Article
Infectious Diseases
Paula MacGregor, Andrea L. Gonzalez-Munoz, Fatoumatta Jobe, Martin C. Taylor, Steven Rust, Alan M. Sandercock, Olivia J. S. Macleod, Katrien Van Bocxlaer, Amanda F. Francisco, Francois D'Hooge, Arnaud Tiberghien, Conor S. Barry, Philip Howard, Matthew K. Higgins, Tristan J. Vaughan, Ralph Minter, Mark Carrington
PLOS NEGLECTED TROPICAL DISEASES
(2019)
Article
Microbiology
Gert-Jan Wijnant, Simon L. Croft, Raul de la Flor, Mo Alavijeh, Vanessa Yardley, Stephanie Braillard, Charles Mowbray, Katrien Van Bocxlaer
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2019)
Review
Parasitology
Diana Caridha, Brian Vesely, Katrien van Bocxlaer, Byron Arana, Charles E. Mowbray, Sima Rafati, Silvia Uliana, Rosa Reguera, Mara Kreishman-Deitrick, Richard Sciotti, Pierre Buffet, Simon L. Croft
INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE
(2019)
Article
Biochemical Research Methods
David J. Clark, Catherine M. Moore, Marc Flanagan, Katrien Van Bocxlaer, Evangelia-Theophano Piperaki, Vanessa Yardley, Simon L. Croft, John Tyson, Sam P. Whitehouse, Jonathan O'Halloran, Sanjeev Krishna, Henry M. Staines
Review
Immunology
Paul M. Kaye, Israel Cruz, Albert Picado, Katrien Van Bocxlaer, Simon L. Croft
SEMINARS IN IMMUNOPATHOLOGY
(2020)
Article
Biochemistry & Molecular Biology
Alaa Riezk, Katrien Van Bocxlaer, Vanessa Yardley, Sudaxshina Murdan, Simon L. Croft
Article
Multidisciplinary Sciences
Helen Ashwin, Jovana Sadlova, Barbora Vojtkova, Tomas Becvar, Patrick Lypaczewski, Eli Schwartz, Elizabeth Greensted, Katrien Van Bocxlaer, Marion Pasin, Kai S. Lipinski, Vivak Parkash, Greg Matlashewski, Alison M. Layton, Charles J. Lacey, Charles L. Jaffe, Petr Volf, Paul M. Kaye
Summary: Leishmaniasis is considered a vaccine-preventable disease, but costs and uncertainty hinder progress in vaccine development. Controlled human infection models offer a way to speed up vaccine development and gain better understanding of disease pathogenesis.
NATURE COMMUNICATIONS
(2021)
Article
Pharmacology & Pharmacy
Katrien Van Bocxlaer, Kerri-Nicola McArthur, Andy Harris, Mo Alavijeh, Stephanie Braillard, Charles E. Mowbray, Simon L. Croft
Summary: In cutaneous leishmaniasis, using film-forming systems for drug delivery shows potential advantages in reducing adverse effects and improving treatment adherence. However, the efficacy of specific compounds like DNDI-0690 using this system requires further investigation and consideration.
Article
Infectious Diseases
Katrien Van Bocxlaer, Jodie Dixon, Johannes J. Platteeuw, Dennie van den Heuvel, Kerri-Nicola Mcarthur, Andy Harris, Mo Alavijeh, Simon L. Croft, Vanessa Yardley
Summary: A drug called OLPC has demonstrated potent activity against CL-causing Leishmania species, and could be a promising alternative to miltefosine treatment for cutaneous leishmaniasis.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
Review
Biochemistry & Molecular Biology
Katrien Van Bocxlaer, Simon L. Croft
Summary: Treatment of cutaneous leishmaniasis involves the release, permeation and accumulation of active compounds in the skin. Evaluating the pharmacodynamic activity of drugs against parasites is relatively straightforward, but understanding the pharmacokinetic processes within the skin is more complex due to various factors such as skin structure and drug distribution.
RSC MEDICINAL CHEMISTRY
(2021)
Article
Microbiology
Gert-Jan Wijnant, Katrien Van Bocxlaer, Vanessa Yardley, Andy Harris, Sudaxshina Murdan, Simon L. Croft
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2018)